Kimberley Maruncic

Kimberley Maruncic

Associate
Kimberley Maruncic
Santa Monica
+1 424 252 6379

Kimberley Maruncic is an associate in the firm’s Business Law department and a member of its Technology and Life Science groups. Ms. Maruncic advises clients on a wide range of corporate matters, including company formation, venture capital financings, mergers and acquisitions and general corporate and securities law. She joined Goodwin in 2018.

Representative Matters

  • BridgeBio Pharma, LLC and Maze Therapeutics joint venture 
  • Blackstone Life Sciences and Ferring joint venture for over $570 million
  • RA Capital and Versant Ventures on their €66 million Series A Financing in T-Knife 
  • Anthos Therapeutics, LLC in its $250 million Series A Preferred Unit Financing  
  • Anthos Theraputics, Inc. in tis $53 million Series A Financing 
  • ElevateBio LLC in its $170 million Series B Financing and $150 million Series A Financing
  • Kymera Therapeutics, Inc. in its $102 million cross-over Series C Financing 
  • Allovir Inc. in its $120 million Series B Financing 
  • ViraCyte, Inc. in its $121 million Series B Financing 
  • Gemini Therapeutics Inc. in its $50 million Series B Financing
  • Numerous other private companies and venture capital firms in connection with equity and convertible debt financings

  • AppNexus in its sale to AT&T.
  • Acquia, Inc. in its sale to Vista Equity Partners 
  • Repligen Corporation in its acquisition of Avitide, Inc.
  • Repligen Corporation in its acquisition ARTeSYN Biosolutions Holdings Ireland Limited
  • Repligen Corporation in its acquisition of Engineered Molding Technology LLC
  • HealthEdge Software, Inc. in its sale to Blackstone
  • Sansoro Health, Inc. in its acquisition of Datica, Inc. 
  • Acquia Inc. in its acquisition of Cohesion Web Technologies Limited 
  • Acquia Inc. in its acquisition of Mautic, Inc. 
  • PlumChoice, Inc. in its sale to SquareTrade, Inc., a subsidiary of Allstate Corporation
  • Mevion Medical Systems, Inc. in its sale to Henan Maisheng Medical Technology Co., Ltd

  • Dynatrace, Inc. in its $862.5 million follow-on offering.
  • Dynatrace, Inc. in its $680 million follow-on offering.
  • Dynatrace, Inc. in its $620 million initial public offering.

Professional Experience

Prior to joining Goodwin, Ms. Maruncic worked as an associate for Davis, Malm & D’Agostine, P.C., Reebok International Ltd. and the Boston Red Sox. Prior to law school, Ms. Maruncic worked as a Client Service Specialist for Gavin Management Group, a management company for professional hockey players.

Credentials

Education

JD2016

Northeastern University School of Law

BAMathematics, concentration in Finance2009

Wilfrid Laurier University

(Honors)

Admissions

Bars

  • Massachusetts
  • New York
  • California